Full-Time

Analyst Data Process Management

Deadline 9/30/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

Remote

Travel may be required based on business need.

Bachelor's, Master's, MBA, PhD

Category
Data & Analytics (1)
Required Skills
Power BI
Veeva
Market Research
Python
Forecasting
SQL
Word/Pages/Docs
Quality Assurance (QA)
AWS
Informatica
Alteryx
Data Governance
Data Analysis
Excel/Numbers/Sheets

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • At least 3 years of direct experience with pharmaceutical commercial datasets, including pharmaceutical sales data and data management, with emphasis on IQVIA syndicated datasets, Specialty Pharmacy, and claims datasets.
  • A bachelor's degree from an accredited four-year college or university.
  • Strong technical background in SQL, Python, Excel, Power BI, Informatica, and AWS.
  • Strong knowledge of pharmaceutical sales and marketing data sources such as IQVIA and Veeva, and knowledge of how data is applied in pharmaceutical commercial operations.
  • Ability to translate business needs into data requirements.
  • Understanding of data and incident management and data processing principles.
  • Understanding of data governance and data stewardship, including data quality.
  • Strong communication skills, including the ability to explain data management subject matter to non-technical or unfamiliar internal customers.
  • Proficiency in Microsoft Excel, Word, and PowerPoint.
  • Problem-solving and strategic-thinking ability, with a focus on ensuring high-quality data output and quality assurance.
  • Ability to synthesize complex information into clear and actionable insights.
  • Ability to work effectively across stakeholder levels and diverse functions.
  • Understanding of pharmaceutical development, manufacturing, supply chain, and marketing functions.
  • Ability to collaborate across differing levels of management, functions, and roles.
  • Strong decision-making skills, including identifying key issues, developing solutions, and gaining commitment.
  • Excellent knowledge of English, both written and spoken.
Responsibilities
  • Ensure timely and accurate delivery of data requirements by collaborating with relevant stakeholders.
  • Maintain data availability, data quality, and data completeness according to requirements and deliver them in a timely manner.
  • Ensure data consistency across sources and downstream teams.
  • Proactively identify data requirements and gaps in systems.
  • Develop standard operating procedures for data management processes and lead process enhancements.
  • Provide training to end users on data usage across sources.
  • Build advanced tools and automate or improve processes for analytical and other needs.
  • Maintain effective relationships with end stakeholders and develop education and communication content as required.
  • Lead and develop SBO operations associates while leveraging new technologies.
  • Initiate the contracting process and related documents within defined timelines.
  • Collaborate with global stakeholders on project planning, timeline setup, and budget maintenance.
  • Ensure data supplied by customer data management is used effectively in commercial operations processes, including forecasting, targeting, call planning, alignments, field reporting, incentive compensation, and market mix.
  • Administer customer data management activities related to the quarterly operations cycle.
  • Monitor data quality reports and investigate problems.
  • Maintain requirements documents, business rules, and metadata.
  • Provide first-level support for sales, claims, master data management, and omnichannel data inquiries.
  • Provide ad hoc support to the United States customer data management team.
  • Develop data management analytics and reporting capabilities.
  • Collaborate with Digital to enhance data access across sources and develop tools, technology, and processes that improve quality and productivity.
  • Support data management activities such as developing a data quality framework, data cataloging, and data profiling.
  • Ensure high standards for output produced by the digital and data management team.
  • Ensure adherence to compliance procedures and internal operational risk controls in accordance with applicable standards.
  • Refresh reports on weekly, monthly, quarterly, and annual cycles, with quality-control checks for each refresh.
  • Manage opt-out compliance for the healthcare professional universe.
  • Work with global teams and external vendors to ensure effective end-to-end project delivery with complete data availability.
Desired Qualifications
  • Experience using artificial intelligence tools to accelerate data governance outcomes.
  • Experience using analytical tools such as Power BI, Visual Basic for Applications, and Alteryx.
  • Experience with analytics teams covering field reporting, field deployment, and incentive compensation.
  • Experience working with vaccines and claims data.
  • An advanced degree in Management, Statistics, Decision Sciences, Engineering, Life Sciences, Business Analytics, or a related field, such as a PhD, MBA, or master's degree.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.